JP2017511379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511379A5 JP2017511379A5 JP2017501529A JP2017501529A JP2017511379A5 JP 2017511379 A5 JP2017511379 A5 JP 2017511379A5 JP 2017501529 A JP2017501529 A JP 2017501529A JP 2017501529 A JP2017501529 A JP 2017501529A JP 2017511379 A5 JP2017511379 A5 JP 2017511379A5
- Authority
- JP
- Japan
- Prior art keywords
- modified antibody
- antibody
- modified
- cysteine
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1405264.1 | 2014-03-24 | ||
| GB201405264A GB201405264D0 (en) | 2014-03-24 | 2014-03-24 | Modified antibodies containing lgG2 Domains which possess agonist or antagonistic properties and therapeutic use thereof |
| GB201405275A GB201405275D0 (en) | 2014-03-25 | 2014-03-25 | Modified antibodies containing lgG2 Domains which possess agonist or antagonistic properties and therapeutic use thereof |
| GB1405275.7 | 2014-03-25 | ||
| PCT/IB2015/052166 WO2015145360A1 (en) | 2014-03-24 | 2015-03-24 | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019204004A Division JP2020037577A (ja) | 2014-03-24 | 2019-11-11 | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511379A JP2017511379A (ja) | 2017-04-20 |
| JP2017511379A5 true JP2017511379A5 (enExample) | 2018-05-17 |
| JP6682498B2 JP6682498B2 (ja) | 2020-04-15 |
Family
ID=52829255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501529A Expired - Fee Related JP6682498B2 (ja) | 2014-03-24 | 2015-03-24 | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 |
| JP2019204004A Pending JP2020037577A (ja) | 2014-03-24 | 2019-11-11 | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019204004A Pending JP2020037577A (ja) | 2014-03-24 | 2019-11-11 | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11059898B2 (enExample) |
| EP (2) | EP3122779B1 (enExample) |
| JP (2) | JP6682498B2 (enExample) |
| CN (2) | CN113912723A (enExample) |
| AU (1) | AU2015237864B2 (enExample) |
| CA (1) | CA2943167A1 (enExample) |
| WO (1) | WO2015145360A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI677507B (zh) | 2012-06-22 | 2019-11-21 | 達特茅斯學院基金會 | 新穎之ｖｉｓｔａ－ｉｇ構築體及ｖｉｓｔａ－ｉｇ用於治療自體免疫、過敏及發炎病症之用途 |
| EP2953634B1 (en) | 2013-02-07 | 2021-05-26 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| SMT202100116T1 (it) | 2014-05-28 | 2021-05-07 | Agenus Inc | Anticorpi anti-gitr e metodi di utilizzo degli stessi |
| DK3151921T3 (da) | 2014-06-06 | 2019-12-02 | Bristol Myers Squibb Co | Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf |
| DK3221363T3 (da) | 2014-11-21 | 2020-08-10 | Bristol Myers Squibb Co | Antistoffer mod cd73 og anvendelser deraf |
| HRP20201756T8 (hr) * | 2014-11-21 | 2021-08-20 | Bristol-Myers Squibb Company | Antitijela koja sadrže modificirane regije teškog lanca |
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| ES2962885T3 (es) | 2015-05-15 | 2024-03-21 | Massachusetts Gen Hospital | Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral |
| CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| CN107743586B (zh) | 2015-06-03 | 2021-07-02 | 百时美施贵宝公司 | 用于癌症诊断的抗gitr抗体 |
| MX395257B (es) | 2015-06-29 | 2025-03-25 | Bristol Myers Squibb Co | Anticuerpos para cd40. |
| EP3340999A4 (en) | 2015-08-28 | 2019-06-12 | The General Hospital Corporation | AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES |
| AU2016332725A1 (en) | 2015-09-29 | 2018-03-22 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
| EP3374399A1 (en) | 2015-11-11 | 2018-09-19 | Opi Vi- IP Holdco LLC | Composition and methods for anti-tnfr2 antibodies |
| BR112018010172A2 (pt) | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| JP7227007B2 (ja) | 2015-12-02 | 2023-02-21 | ストサイエンシス， インコーポレイテッド | グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体 |
| EP3448412A4 (en) * | 2016-04-15 | 2020-03-25 | Immunext Inc. | ANTI-HUMAN-VISTA ANTIBODIES AND USE THEREOF |
| CN116715767A (zh) | 2016-05-13 | 2023-09-08 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
| BR112018073739A2 (pt) | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | proteína de ligação de albumina sérica de domínio único |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して白斑を治療する方法 |
| US10751414B2 (en) | 2016-09-19 | 2020-08-25 | Celgene Corporation | Methods of treating psoriasis using PD-1 binding antibodies |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| EP3666794A1 (en) | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
| US11535668B2 (en) * | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| GB201712032D0 (en) * | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| UA128472C2 (uk) | 2017-08-25 | 2024-07-24 | Файв Прайм Терапеутікс Інк. | B7-h4 антитіла і методи їх використання |
| IL272770B2 (en) * | 2017-09-19 | 2025-08-01 | Mab Discovery Gmbh | Agonistic cd40 antibodies |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| UA129446C2 (uk) | 2017-10-13 | 2025-04-30 | Гарпун Терап'Ютікс, Інк. | Триспецифічні білки і способи їх застосування |
| KR102813744B1 (ko) | 2017-12-27 | 2025-05-28 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd40 항체 및 그의 용도 |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| BR112020016986A2 (pt) | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| CA3091801A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN118994395A (zh) | 2018-07-20 | 2024-11-22 | 皮埃尔法布雷医药公司 | Vista受体 |
| US20210340268A1 (en) * | 2018-08-20 | 2021-11-04 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| CN113039201A (zh) * | 2018-09-28 | 2021-06-25 | 礼进生物医药科技（上海）有限公司 | 具有经过工程化的Fc结构域的抗CD137结合分子及其治疗用途 |
| WO2020102739A1 (en) * | 2018-11-15 | 2020-05-22 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
| GB201820547D0 (en) * | 2018-12-17 | 2019-01-30 | Oxford Univ Innovation | Modified antibodies |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| EP3927747A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| CN112592404B (zh) * | 2019-09-20 | 2023-07-25 | 上海交通大学医学院 | 抗体活性改造及其筛选方法 |
| CN113416258B (zh) * | 2019-10-24 | 2023-08-29 | 北京免疫方舟医药科技有限公司 | 一种多特异性抗体及其制备方法和用途 |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| WO2021183428A1 (en) | 2020-03-09 | 2021-09-16 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
| WO2022159675A2 (en) * | 2021-01-21 | 2022-07-28 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| HRP20250696T1 (hr) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | Sastavi i postupci za liječenje sindroma oslobađanja citokina |
| WO2024121380A1 (en) | 2022-12-08 | 2024-06-13 | Pierre Fabre Medicament | Vaccinal composition and adjuvant |
| EP4560319A1 (en) | 2023-11-24 | 2025-05-28 | Pierre Fabre Medicament | Immune and tumour cells expression of vista in a panel of cancer indications |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| WO1994021293A1 (en) | 1993-03-19 | 1994-09-29 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| ATE306930T1 (de) | 1994-08-12 | 2005-11-15 | Immunomedics Inc | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| WO2005007809A2 (en) * | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| RU2377254C2 (ru) * | 2003-12-25 | 2009-12-27 | Кирин Фарма Кабусики Кайся | Мутанты анти-cd40 антитела |
| AU2006204459B2 (en) * | 2005-01-05 | 2012-11-01 | F-Star Therapeutics Limited | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| US8716451B2 (en) * | 2005-01-12 | 2014-05-06 | Kyowa Hakko Kirin Co., Ltd | Stabilized human IgG2 and IgG3 antibodies |
| US7585960B2 (en) | 2005-05-11 | 2009-09-08 | Theramab Gmbh | Nucleic acids encoding superagonistic anti-CD28 antibodies |
| MX2008007140A (es) | 2005-12-09 | 2009-03-04 | Seattle Genetics Inc | Metodos para utilizar agentes de union a cd40. |
| BRPI0811857A2 (pt) * | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
| AR074438A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal |
| JP5694921B2 (ja) * | 2009-04-20 | 2015-04-01 | 協和発酵キリン株式会社 | アミノ酸変異が導入されたＩｇＧ２を有する抗体 |
| JP5469390B2 (ja) * | 2009-07-15 | 2014-04-16 | 日立コンシューマエレクトロニクス株式会社 | 再生信号評価方法及び記録調整方法 |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| KR102049991B1 (ko) | 2013-03-28 | 2019-12-02 | 삼성전자주식회사 | 항 c-Met/항 Her2 이중 특이 항체 |
-
2015
- 2015-03-24 WO PCT/IB2015/052166 patent/WO2015145360A1/en not_active Ceased
- 2015-03-24 EP EP15716147.2A patent/EP3122779B1/en active Active
- 2015-03-24 CA CA2943167A patent/CA2943167A1/en active Pending
- 2015-03-24 CN CN202111024797.5A patent/CN113912723A/zh active Pending
- 2015-03-24 EP EP19175308.6A patent/EP3590967A1/en not_active Withdrawn
- 2015-03-24 CN CN201580023010.XA patent/CN107172880B/zh not_active Expired - Fee Related
- 2015-03-24 AU AU2015237864A patent/AU2015237864B2/en not_active Ceased
- 2015-03-24 US US15/128,781 patent/US11059898B2/en not_active Expired - Fee Related
- 2015-03-24 JP JP2017501529A patent/JP6682498B2/ja not_active Expired - Fee Related
-
2019
- 2019-11-11 JP JP2019204004A patent/JP2020037577A/ja active Pending
-
2021
- 2021-05-24 US US17/327,837 patent/US20210347907A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017511379A5 (enExample) | ||
| Buchan et al. | The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy | |
| Madireddi et al. | Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies | |
| US12077592B2 (en) | GPRC5D chimeric antigen receptors and cells expressing the same | |
| KR102745835B1 (ko) | Tigit- 및 light-기반 키메라 단백질 | |
| JP2022064949A (ja) | 条件付活性ヘテロ二量体ポリペプチド及びその使用方法 | |
| Ferris et al. | Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion | |
| Shimizu et al. | Stimulation of CD25+ CD4+ regulatory T cells through GITR breaks immunological self-tolerance | |
| Croft | The role of TNF superfamily members in T-cell function and diseases | |
| JP6666267B2 (ja) | Ｏｘ４０ｌ融合タンパク質およびその使用 | |
| JP5883384B2 (ja) | 免疫機能を調節する方法 | |
| Yu et al. | In vitro evidence that cytokine receptor signals are required for differentiation of double positive thymocytes into functionally mature CD8+ T cells | |
| Desbarats et al. | Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells | |
| WO2020097346A1 (en) | ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF | |
| IL277398B1 (en) | Pd-l1 binding affimers, and uses related thereto | |
| JP2018524326A5 (enExample) | ||
| JP2017533207A5 (enExample) | ||
| Khan et al. | Cloning, expression, and functional characterization of TL1A-Ig | |
| JP2017511379A (ja) | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 | |
| Eun et al. | 4-1BB ligand signaling to T cells limits T cell activation | |
| US11111310B2 (en) | Chimeric polypeptides and methods of altering the membrane localization of the same | |
| CA3169949A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| US20210284712A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| CN114423497A (zh) | 修饰的细胞毒性t细胞及其使用方法 | |
| US20220220186A1 (en) | Chimeric co-stimulatory proteins comprising mutant intracellular domains with increased expression |